Patient reported outcomes among treatment modalities for prostate cancer

被引:0
|
作者
Johnson, Matthew E. [1 ]
Zaorsky, Nicholas G. [1 ]
Martin, Jeffrey M. [1 ]
Ruth, Karen [2 ]
Greenberg, Richard E. [3 ]
Uzzo, Robert G. [3 ]
Hayes, Shelly B. [1 ]
Smaldone, Marc C. [3 ]
Kutikov, Alexander [3 ]
Viterbo, Rosalia [3 ]
Chen, David Y. T. [3 ]
Hallman, Mark A. [1 ]
Sobczak, Mark L. [1 ]
Horwitz, Eric M. [1 ]
机构
[1] Fox Chase Canc Ctr, Dept Radiat Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA
[2] Fox Chase Canc Ctr, Dept Biostat, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Urol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
关键词
sexual function; brachytherapy; prostate cancer; prostatectomy; radiation therapy; quality of life; comparative effectiveness research; personalized medicine; treatment selection; toxicity; genitourinary; gastrointestinal; QUALITY-OF-LIFE; DOSE-RATE BRACHYTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; CLINICAL TARGET VOLUME; RADIATION-THERAPY; RADICAL PROSTATECTOMY; CONSENSUS GUIDELINES; AMERICAN BRACHYTHERAPY; ADVANCED TECHNOLOGY; URINARY;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: To characterize patient reported outcomes for urinary and sexual function using International Prostate Symptom Score (IPSS) and Sexual Health Inventory for Men (SHIM) comparing intensity modulated radiation therapy (IMRT), low dose rate brachytherapy (LDR), post-prostatectomy IMRT (PPRT), and radical prostatectomy (RP). Materials and methods: Patients treated for prostate cancer from 2001-2012 completed self-reported SHIM and IPSS surveys. Subgroups were created by baseline score. Mean change from baseline was determined at each time point for the cohort and subgroups. Statistical analysis was performed with generalized estimating equation method. Incontinence was not captured in the questionnaires. Results: A total of 14,523 IPSS surveys from 3,515 men were evaluated. Patients treated with IMRT experienced a minimal decrease in IPSS score from baseline. PPRT scores did not differ from IMRT at any time point (range: +1-3 points from baseline in IPSS score over 50 months). LDR had an initial IPSS rise (between 5-10 points on the IPSS over 1-9 months) versus IMRT but returned to comparable levels at 34 months. RP was associated with a lower IPSS versus IMRT. LDR had the largest rise from baseline, with return toward baseline. A total of 2,624 SHIM surveys from 857 men were evaluated. LDR and PPRT did not differ from IMRT at any time point (range: +1-5 points from baseline in SHIM score for 36 months). RP experienced the largest decline from baseline (up to -7 points on SHIM score), at 3 to 7 months; RP had a larger early decrease in SHIM score versus IMRT between 3 and 22 months, after which there was no difference. Conclusions: IPSS and SHIM score patterns differed among treatment modalities. These data can be used to predict changes in urinary and sexual function over time based on modality and baseline score.
引用
收藏
页码:8535 / 8545
页数:11
相关论文
共 50 条
  • [41] Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer Helping Decision Making for Patients and Their Physicians
    Hamdy, Freddie C.
    Donovan, Jenny L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (11): : 1121 - 1123
  • [42] Patient-Reported Outcomes Among Adults with Hemophilia A on Prophylactic Treatment
    Chupka, Janet
    Decker-Palmer, Marquita
    Lin, Chia-Wei
    Martin, Ashley
    Modi, Kushal
    Bates, Dawn
    Thomson, Karen
    BLOOD, 2022, 140 : 10893 - 10894
  • [43] Patient-reported outcomes after curative treatment for prostate cancer with prostatectomy, primary radiotherapy or salvage radiotherapy
    Saelen, Marie G.
    Hjelle, Line V.
    Aarsaether, Erling
    Knutsen, Tore
    Andersen, Sigve
    Bentzen, Anne G.
    Richardsen, Elin
    Fossa, Sophie D.
    Haugnes, Hege S.
    ACTA ONCOLOGICA, 2023, 62 (06) : 657 - 665
  • [44] Patient-reported and clinical outcomes among patients with pancreatic cancer
    Pichardo, Rayli
    Jacob, Brigid
    Jamil, Maria
    Jamil, Dawood
    Raslan, Shahm
    Rose, Courtney M.
    Boakye, Eric Adjei
    Poisson, Laila
    Tam, Samantha
    Philip, Philip A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Clinical-Prostate cancer Functional outcomes after prostate cancer treatment: A comparison between single and multiple modalities
    Muise, Alexandra
    Pan, Michael M.
    Rose, Brent
    Buckley, Jill C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (02) : 104.e1 - 104.e9
  • [46] Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients
    Smith, Angela B.
    Samuel, Cleo A.
    McCabe, Sean D.
    Deal, Allison
    Jonsson, Mattias
    Mueller, Dana E.
    Mahbooba, Zahra M.
    Bennett, Antonia, V
    Chung, Arlene E.
    Nielsen, Matthew E.
    Tan, Hung-Jui
    Wallen, Eric
    Pruthi, Raj
    Wang, Andrew
    Basch, Ethan
    Reeve, Bryce B.
    Chen, Ronald C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (01) : 77.e1 - 77.e8
  • [47] Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: Patient reported use and outcomes from the surveillance, epidemiology, and end results prostate cancer outcomes study
    Stephenson, RA
    Mori, M
    Hsieh, YC
    Beer, TM
    Stanford, JL
    Gilliland, FD
    Hoffman, RM
    Potosky, AL
    JOURNAL OF UROLOGY, 2005, 174 (02): : 646 - 650
  • [48] Comparing outcomes of external radiotherapy modalities for prostate cancer
    Igdem, Sefik
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2014, 13 (01): : 29 - 32
  • [49] Neoadjuvant and adjuvant treatment modalities for prostate cancer
    Erkan, Erkan
    Toktas, Gokhan
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (02): : 63 - 69
  • [50] Targeted nanomedicine modalities for prostate cancer treatment
    Cohen, Lital
    Livney, Yoav D.
    Assaraf, Yehuda G.
    DRUG RESISTANCE UPDATES, 2021, 56